ChromaDex (NASDAQ:CDXC) Stock Price Expected to Rise, LADENBURG THALM/SH SH Analyst Says

ChromaDex (NASDAQ:CDXC - Free Report) had its price objective upped by LADENBURG THALM/SH SH from $6.80 to $8.10 in a report published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms also recently weighed in on CDXC. StockNews.com upgraded ChromaDex from a "buy" rating to a "strong-buy" rating in a research report on Monday, February 24th. Roth Mkm increased their price objective on ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday, November 6th.

ChromaDex Trading Up 0.1 %

Shares of ChromaDex stock traded up $0.01 on Wednesday, hitting $7.70. 1,083,271 shares of the company traded hands, compared to its average volume of 865,008. ChromaDex has a 12-month low of $1.61 and a 12-month high of $9.18. The company has a market cap of $598.68 million, a P/E ratio of 770.77 and a beta of 2.21. The firm's 50-day simple moving average is $5.77 and its 200 day simple moving average is $5.20.

Insider Activity at ChromaDex

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business's stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the sale, the director now owns 244,179 shares of the company's stock, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 9.64% of the stock is owned by insiders.

Remove Ads

Hedge Funds Weigh In On ChromaDex

A number of large investors have recently bought and sold shares of CDXC. Barclays PLC boosted its stake in shares of ChromaDex by 322.1% during the third quarter. Barclays PLC now owns 70,072 shares of the company's stock valued at $256,000 after purchasing an additional 53,472 shares during the period. Sargent Investment Group LLC purchased a new stake in ChromaDex during the 4th quarter valued at $263,000. FMR LLC purchased a new stake in ChromaDex during the 3rd quarter valued at $55,000. JPMorgan Chase & Co. grew its holdings in ChromaDex by 11.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company's stock worth $1,211,000 after acquiring an additional 33,150 shares during the last quarter. Finally, State Street Corp increased its position in shares of ChromaDex by 11.3% in the third quarter. State Street Corp now owns 618,028 shares of the company's stock valued at $2,256,000 after acquiring an additional 62,692 shares during the period. 15.41% of the stock is owned by hedge funds and other institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.